Contrasting Oncology Pharma (OTCMKTS:ONPH) and Centessa Pharmaceuticals (NASDAQ:CNTA)

Centessa Pharmaceuticals (NASDAQ:CNTA) and Oncology Pharma (OTCMKTS:ONPH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Centessa Pharmaceuticals and Oncology Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1	0	9	2	3.00
Oncology Pharma	0	0	0	0	0.00

Centessa Pharmaceuticals presently has a consensus price target of $34.78, indicating a potential upside of 22.37%. Given Centessa Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Centessa Pharmaceuticals is more favorable than Oncology Pharma.

Institutional and Insider Ownership

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 7.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 18.0% of Oncology Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Centessa Pharmaceuticals and Oncology Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$6.85 million	557.70	-$235.76 million	($1.83)	-15.53
Oncology Pharma	N/A	N/A	N/A	N/A	N/A

Oncology Pharma has lower revenue, but higher earnings than Centessa Pharmaceuticals.

Volatility & Risk

Centessa Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Oncology Pharma has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Profitability

This table compares Centessa Pharmaceuticals and Oncology Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-49.39%	-34.64%
Oncology Pharma	N/A	N/A	N/A

Summary

Centessa Pharmaceuticals beats Oncology Pharma on 7 of the 10 factors compared between the two stocks.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

About Oncology Pharma

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.